enews
International Federation of Clinical Chemistry
and Laboratory Medicine

Communications and Publications Division (CPD) of the IFCC
Editor: Katherina Psarra, MSc, PhD
IFCC Office, Via C. Farini, 81
20159 Milano, Italy
E-mail: enews@ifcc.org

news

№ 7/8
July-August 20241

enewsIn this issue
The voice of IFCC
Message from the IFCC President

4

IFCC Professional Scientific Exchange Programme: My experience at the Instituteof Metabolic Science - Metabolic Research Laboratories, University of Cambridge,
United Kingdom

5

IFCC Professional Scientific Exchange Programme: My experience at Protein
Immunology Lab (PIL), Department of Laboratory Medicine and Pathology (DLMP),
Mayo Clinic, Rochester, USA.

7

IFCC Professional Scientific Exchange Programme: My experience at San Giovani
di Dio Hospital, in Florence, Italy

10

IFCC Professional Scientific Exchange Programme: My experience incomputational medicine, using artificial intelligence in laboratory medicine inBern, Switzerland

11

IFCC Professional Scientific Exchange Programme - My experience in Oslo,
Norway13

IFCC Abbott Visiting Lecture Programme (VLP) - 2024 CSCC / SQBC Joint
Conference - Mont Sainte-Anne, Quebec, Canada

15

IFCC Abbott Visiting Lecturer Programme (VLP) - V Jornadas Científicas Julias- V
Jornadas Internacionales 2024 - La Paz, Bolivia

17

IFCC: the people
Interview with Prof. Dr. Tomris Ozben, IFCC President

18

Call for nominations

23

IFCC: the Young Scientists
IFCC WorldLab 2024 – Dubai through Young Scientists’ Eyes part 2

24

Contribute to IFCC eNews
Twelve Integrated Clinical Care Teams Receiving Recognition Through the
UNIVANTS of Healthcare Excellence Awards

28

Impact of luminescence in Clinical Laboratories

31

News from Regional Federations and Member Societies
Uniting Visionaries: Reflections on the 4th Annual Congress of the Nepalese
Association for Clinical Chemistry34

2

IFCC’s Calendar of Congresses, Conferences & Events
IFCC and Regional Federations events

38

Corporate Member events with IFCC auspices

39

Other events with IFCC auspices

40

3

The voice of IFCC
IFCC and Congress President’s Welcome Message
July 2024
By Tomris Ozben

Dear Colleagues and Friends,
I hope this message finds you well. I’m pleased to share some key updates
from the IFCC, as our activities continue to thrive even during the summer
months.
Firstly, I want to emphasize our ongoing commitment to supporting young
scientists through specific programmes and initiatives. Through the IFCC
Task Force the we are offering workshops, mentorship programs, andcollaborative research opportunities (PEP) for young scientists to learn,
grow, and contribute to the scientific community.
National society meetings continue to be a cornerstone for laboratory
professionals, providing essential platforms for knowledge exchange
and professional growth. I encourage you to actively engage in thesemeetings.

Prof. Tomris Ozben
EuSpLM, Ph.D.

Our webinars continue to be a great success. Recently, we had an
insightful, and very well-attended session on Different Approaches to
Bioethics, addressing the issues related to the use of data through AI,
and I’m pleased to announce that our next webinar will focus on Minimum
quality specifications based on the state of the art, is scheduled for
September. The contribution of respected and authoritative speakers
helps keep the IFCC community at the forefront of clinical chemistry andlaboratory medicine.
Additionally, I want to draw your attention to the call for studies by
the Task Force on Outcome Studies in Laboratory Medicine (TF-OSLM).
This is a great opportunity to contribute to impactful research andadvancements in our field. Don’t miss the opportunity to submit yourproposal – see all details in the following pages.
I’m also delighted to see an increasing number of corporate members
participating in the IFCC activities and showing interest in EuroMedLab
Brussels. Their participation underscores the growing collaboration
between the IFCC and industry, which is crucial for our collective progress.
Lastly, I’m excited to announce that we will be organizing a General
Conference—the usual IFCC family meeting. This will be a wonderfuloccasion for us to come together, share our experiences, and envision the
future course of our federation.
As we move through the summer, I invite all members and partners tostay engaged and participate in these exciting initiatives. Thank you foryour continued dedication and contributions to the IFCC community.
With my best regards
Prof. Dr Tomris Ozben
IFCC President

4

IFCC Professional Scientific Exchange
Programme
My experience at the Institute of Metabolic Science- Metabolic Research Laboratories, University ofCambridge, United Kingdom
By Dr Ifeyinwa Nnakenyi MBBS, MSc, FMCPath, FWACP, Senior Lecturer and Honorary Consultant
Chemical Pathologist, University of Nigeria Nsukka & University of Nigeria Teaching Hospital, Enugu
state, Nigeria

I spent an exciting two months at the Institute of Metabolic Science - Metabolic Research Laboratories,of the prestigious University of Cambridge, United Kingdom for the IFCC Professional Scientific Exchange
Programme.
It was an ideal center equipped with state-of-the-art facilities to enable me experience advanced
research techniques and skills involved in the length and breadth of metabolic research. There were topnotch facilities for cell culture, pathology, genetic studies, mouse models, human studies, and much more.
I was exposed to high-level laboratory techniques such as advanced immunoassays like the Mesoscale
Discovery Multiplex, and the ‘omics’ (lipidomics, metabolomics, proteomics, peptidomics, genomics,
transcriptomics), and developed skills in preparing and validating blank ELISA plates using commercial
antibodies. This skill amongst others enabled the successful conduction of my research work where I
analyzed certain obesity biomarkers in blood samples of Nigerian breast cancer females at the Core
Biochemical Assay Laboratory.
I observed data and sample collection for several research activities like Fibroscan for fatty liver, Dexa
Scan for body fat and lean mass percentages, adipose tissue biopsies for RNA analysis, euglycemic
insulin clamp test, and oral glucose tolerance test. As well as observed current patient management ofobesity and metabolic diseases at Addenbrooke’s hospital of the Cambridge University Hospital Trust.
I participated in several seminars which boosted my research ideas, and attended multi-disciplinary
research meetings to hone communication skills with collaborators. I met and interacted with several
renowned Principal Investigators from within and outside the institute, including reputable names in
the field of obesity genetics and severe insulin resistance like Professor Giles Yeo and Professor Sadaf
Farooqi.
I thoroughly appreciate my gracious host - Professor Sir Stephen O’Rahilly, Head of the Departmentof Clinical Biochemistry and Director of the Medical Research Council -Metabolic Research Diseases
Unit, who is renowned for his research into the molecular pathogenesis of human obesity and insulin
resistance. He granted me access to all required facilities and personnel making my visit very fulfilling.
He was instrumental in making me an Associate Scholar of Pembroke college were I resided, which was
proximal to the sights and sounds of Cambridge city. During my stay, I enjoyed fine dining at the formal
dinners, going to the opera and punting for the first time. I made some good friends with whom I shared
happy memories.
It was indeed a wonderful time and I am eternally grateful to the IFCC Professional Scientific Exchange
Program for this opportunity that broadened my horizon on so many levels.

Article continued on the next page

5

IFCC PSEP: My experience at the Instituteof Metabolic Science, Cambridge, UK

With my host- Professor Sir Stephen O’Rahilly – Consultant

Conducting my research work in the laboratory

Endocrinologist Head of Department of Clinical Biochemistry,
University of Cambridge, UK

With members of staff of the Core Biochemistry Assay
Laboratory

6

IFCC – PSEP
My experience at Protein Immunology Lab (PIL),
Department of Laboratory Medicine and Pathology(DLMP), Mayo Clinic, Rochester, USA.
By Dr. Avinash R. Pagdhune Assistant Professor, Biochemistry, Advanced Centre for Treatment,
Research and Education in Cancer, (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, India.

I got the excellent opportunity to visit Protein Immunology Lab (PIL), At Mayo Clinic Rochester, MN, USA
as Visiting laboratory professional, from 6th Feb to 11th April, 2024. I was hosted by Dr. David Murray,
M.D, Ph.D. Consultant and Co- Director, PIL, Department of Laboratory Medicine and Pathology (DLMP),
Mayo Clinic, Rochester.
Primary aim of visit was to learn and experience the Mass spectrometry based immunoglobulins lightchain assay (MASS FIX), standardization, analysis, interpretation and troubleshooting.
Following Learning objective were completed•••

Bench shadowing of MALDI TOF analysis for immunoglobulins. (MASS FIX)
Identify finding and prevalence of monoclonal antibody therapies identified by different mass spec
methods.
Discussions on Therapeutic monoclonal drugs, Consultants sign outs.

During my visit at PIL, small project work done.
Title: Characterization of MASS FIX Clonal Peaks.
Aim was evaluating analytical CV (Precision) of m/z ratios for immunoglobulins and its isoforms.
Objectives:
•
•
•
•

•

To assess and analyze the m/z ratios for Immunoglobulins and its isoforms in samples from patientswith Plasma Cell Dyscrasias.
To test Suitability of m/z ratio for Measurable residual disease (MRD). Study reveals,•
Precision of m/z over the period on repeated testing, based on the CVs.
Not primitive to say, MASS FIX is very less invasive (noninvasive) test for Sustainable Measurable
Residual Disease (MRD) monitoring which can be considered for Plasma Cell Discrasia (PCD) patients.
MASS FIX: It’s a package test which not only gives information of Ig & its Isoforms, quantification of‘M’ protein, integrated nephelometric measurements of Ig G, A, M for diagnosis of gammopathies
but also provides very useful information on the current Status of disease as well as monitoring of
disease, drugs (TmAbs), Immune response and glycosylation.
It will help to understand the dynamics of monoclonal gamopathies.

Shared the finding with the laboratory technologist audience. Bench shadowing of other technologies
in protein immunology lab like cryoprecipitate, LCMS validation process, Complements testing was also
done.

Article continued on the next page

7

IFCC –PSEP My experience at Protein
Immunology Lab (PIL), Department ofLaboratory Medicine and Pathology (DLMP),
Mayo Clinic, Rochester, USA.

Impact of the project:
Dissemination of knowledge, development of efficient human resources for MASS FIX
1.

Will get trained personnel for high end technologies at the institute.

2.

Can provide wider and accurate test menu for myeloma testing.

3.

Overall robust and precise testing facilities at apex cancer care centre in India.

In the laboratory, I have received insight to detailing of the MASS FIX test and its development
process since last decade. I also got privileged to attend the lab leadership meetings where I havelearnt how laboratory works for its smoother functioning and best of its for patient care services.
I loved the way of technician’s work patterns and their dedication for the test, the real heroes in
the labs which remains unsung many times but I have learnt many things from them at Mayo clinic
laboratories and I appreciate their efforts to make me understand the technique.
Evidences like publications and scientific data shows, the MASS FIX technique is very specific andsensitive too for diagnosis of Monoclonal gammopathies. Protein Immunology lab is very systematicand meticulously works for the various tests in spite of very heavy work load.
I would like to express my sincere gratitude to Dr. David Murray, M.D, Ph.D. Consultant and CoDirector, PIL, Department of Laboratory Medicine and Pathology (DLMP), Mayo Clinic for giving me thegolden opportunity to learn MASS FIX technique i.e. “Joy of MASS FIX” and the hospitality provided
by him and his team. Dr. Murray is very passionate about his work and the listening to him wasamazing experience for me.
I considered very fortunate to have the opportunity to visit such a great institute with the support
from IFCC PSEP. I am heartfelt thankful & grateful to IFCC for making my visit in memorable
experience & fruitful. This visit will for sure make difference in my future path.
Exchange programme definitely benefit both the institutes for Academics, Skill development,
escalate Laboratory Services, Networking & collaborative studies in the future.
For me the experience it’s just “Awesome”.
I want to Acknowledge, for recommending me for the visit.
AMBI-ASSOCIATION OF MEDICAL BIOCHEMIST OF INDIA.
Dr. Navin Khattry, Deputy Director, Clinical Research Centre, ACTREC, TMC, Navi Mumbai.
Dr. Preeti Chavan, OIC, Composite Lab, ACTREC, TMC, Navi Mumbai.
This journey wouldn’t have been possible and successful without their support.

Article continued on the next page

8

IFCC –PSEP My experience at Protein
Immunology Lab (PIL), Department ofLaboratory Medicine and Pathology (DLMP),
Mayo Clinic, Rochester, USA.

Group photo with Avinash R. Pagdhune (left), IFCC PSEP

Avinash R. Pagdhune (left), and Dr. David Murrayparticipant and Dr. David Murray (center) and colleagues

9

IFCC – PSEP
My experience at San Giovani di Dio Hospital, in Florence,
Italy
By Dr Emilda Belortaja Healthcare Center of Vore, Vore/Tirana, Albania

Immunofluorescence microscopy is more than just a scientific technique—it is a lifelong romance, apassion that has fuelled my curiosity, has driven my ambition, and has inspired my pursuit of knowledge
since the first time I was introduced with it. It was a dream come true, the opportunity given to me by
IFCC to practice it in San Giovani di Dio Hospital, in Florence. I will always be grateful to IFCC for this great
opportunity. The heart of my internship lay in the laboratory, where I immersed myself in the art andscience of immunofluorescence assays. Immunofluorescence, with its ability to visualize proteins within
the cellular landscape, offered a captivating glimpse into the dynamic interactions that govern cellularfunction. As the fluorescence microscope came to life, I witnessed the magic unfold before my eyes. With
each click of the shutter, a symphony of colours emerged, painting a vivid portrait of protein distribution
and cellular organization. From the nucleus to the cytoplasm, from the cell membrane to the intricate
network of organelles, immunofluorescence microscopy revealed the hidden architecture of the cell in
exquisite detail. As I journey forward, I embrace the thrill of discovery, the joy of exploration, and theenduring romance of scientific inquiry, fuelled by my unwavering love for immunofluorescence.
Top of FormAs I reflect on my time in the laboratory of immunology at San Giovani di Dio Hospital, the warmth andkindness of the staff, especially the head of laboratory doctor Mariangela Manfredi and doctor Maria
Infantino and biologist Valentina Grossi left a lasting impression on my heart and mind. Their unwavering
support, genuine camaraderie, and acts of kindness have not only enriched my internship experiencebut have also shaped my outlook on teamwork, collaboration, and human connection. As I reflect on myinternship experience in Florence, I am filled with gratitude for the lessons learned, the relationships
forged, and the memories cherished. From navigating unfamiliar streets to embracing new culinary
delights, each moment became a testament to the transformative power of stepping outside one’s
comfort zone. As I return home, I carry with me a renewed sense of purpose, a deeper appreciation fordiversity, and a commitment to being a global citizen and advocate for positive change.

Dr Emilda Belortaja at the microscope in the Laboratory of

Immunofluorescence microscopy

San Giovanni di Dio Hospital in Florence

10

IFCC – PSEP
My experience in computational medicine in Bern: using
artificial intelligence in laboratory medicine.
By Marta Bello Rego Laboratory Medicine, University Hospital of Vigo (Spain)

My name is Marta Bello Rego and I am a pharmacist and final year resident in Laboratory Medicine at
the University Hospital of Vigo (Spain). I have always had a strong interest in computer science andprogramming, especially its applications in the clinical laboratory.
During my residency, I had the opportunity to choose a laboratory for a two-month external rotation.
I chose the group of Prof. Dr. Alexander Leichtle, Inselspital, Department of Clinical Chemistry, Bern
University Hospital, Bern, Switzerland). I am very grateful to have spent this time under his mentorship at
SITEM (Swiss Institute for Translational and Entrepreneurial Medicine) and the Inselspital, where I focusedon learning the application of artificial intelligence and computational tools in laboratory medicine.
Dr. Leichtle is a renowned expert in laboratory medicine and heads a research group specializing incomputational medicine, predictive modeling and machine learning. His group’s work spans statisticalmodeling, analysis of large data sets (e.g., metabolomics), clinical data warehousing, and predictivemodeling. They aim to bridge data-generating medical disciplines and data science to provide predictive
and diagnostic insights.
During my stay, I had two main goals: to deepen my understanding of computational medicine andits applications in laboratory medicine, I developed an R package to verify the agreement between
laboratory methods and presented a draft publication highlighting the importance of implementing suchtools for method comparison. This project greatly enhanced my programming skills and their application in
the clinical laboratory. To expand my expertise in artificial intelligence, I attended courses on AI at SITEM
and gained exposure to cutting-edge applications in translational and entrepreneurial medicine.
Dr. Leichtle and his team welcomed me warmly and treated me as another member of the group. I lookforward to continuing our collaboration and applying my knowledge of computational medicine andartificial intelligence in the clinical laboratory.
The importance of artificial intelligence and computational medicine in laboratory diagnostics cannot be
overstated. Predictive modeling, machine learning, and data analysis tools enable us to uncover patterns
and insights that can improve diagnostic accuracy and patient care. By developing and implementing
computational tools, we can streamline laboratory workflows, improve data interpretation, and facilitate
personalized medicine approaches.
I would like to thank Prof. Dr. Alexander Leichtle for his unwavering support and guidance during myrotation, which fostered my interest in computational medicine and helped me maximize my learning
opportunities. I would also like to thank Drs. Elías Álvarez and Covadonga Fernández for having faith inme, fostering my passion for artificial intelligence, helping me set and focus on the goals of this rotation
to get the most out of it, and Dr. Arturo Fernández Nogueira for allowing and supporting me to complete
this rotation.
I would also like to thank the International Federation of Clinical Chemistry (IFCC), the Spanish Society ofLaboratory Medicine (SEQCML) and the Fundación José Luis Castaño-SEQC for their support through theProfessional Exchange Program (PEP) scholarship. I recommend this experience to other residents andyoung laboratory professionals.

Article continued on the next page11

IFCC –PSEP My experience in computational
medicine in Bern: using artificial intelligence inlaboratory medicine.

Marta Bello Rego with Bern (Switzerland) in the background

Marta Bello Rego, IFCC PSEP and Prof. Dr.
Alexander Leichtle

12

IFCC - PSEPMy Experience in Oslo, Norway
By Mulato Melese Derebe Bahir Dar University, Biotechnology Research Institute Bahir Dar, Ethiopia

The IFCC exchange program activities hosted at Norwegian institute of Public Health (NIPH) Norway,
was started by refreshing samples transported from Ethiopia and conducting isolate identification
by MALDI-TOF techniques to have pure isolates of Neisseria gonorrhea. The pure isolates were
subjected to a phenotypic antimicrobial susceptibility test (AST) and genomic analysis. The genomic
DNA was extracted from pure bacterial culture and went through preparing DNA libraries for wholegenome sequencing. The Whole Genome Sequencing (WGS) was done using Illumina NextSeq 550. The
bioinformatics data analysis was characterized using the multi-locus sequence typing (MLST) schemefrom PubMLST and NG-STAR (Antimicrobial Sequence Type). The write-up of these findings has started
and continued for publication as my PhD study.
During this PSEP program, I was thrilled to be surrounded by senior molecular biology experts who arealso highly qualified and competent researchers. With significant outcomes from the study findings,
I have been able to apply the molecular techniques, drug resistance testing, and bioinformatics skills
I acquired. Every one of my expectations was met, and in many instances exceeded my trip under
the defined objectives of the planned activities. In addition, during my visit, attending academic
conferences, seminars, and other activities often benefit learning and foster my interpersonalconnections.
Beyond what I have mentioned, my PSEP appointment with IFCC support was very across-the-board
and filled the gaps in my knowledge and skill set related to genomics, next-generation sequencing
technologies, and interpretation and data analysis through different tools of bioinformatics. In thisregard, IFCC has awarded the PSEP program and covered the transport, accommodation, and related
expenses. The communication through these processes was responsive and flexible to meet the aimsof the trip. In this process, the IFCC president, executive board members, and office representatives
had gratefully cooperative with their swift response and best networking relationship in order to help
the beneficiary and do a better job. I have special thanks and want to express my gratitude to Silvia(IFCC office) for her flexibility, willingness to help and the efforts and extra time you have contributed
to the process of this PSEP. Again, I would like to transfer my great thanks to EMLA and IFCC for thissignificant support to achieve my academic career and research experience.
I’m beyond grateful for the support of IFCC and the team you gave me for this success.”

Article continued on the next page

13

IFCC Professional Scientific Exchange
Programme – My Experience in Oslo, Norway

Mulatu with Dr. Bente Borud, supervisor and lead researcher,
NIPH

Mulato Melese Derebe in the Bacteriology
Laboratory

Exit meeting with professors and researchers at NIPH
including memorial award from my Supervisor Dr. Bente Borud

14

IFCC-Abbott Visiting Lecturer Program (VLP) 2024
CSCC / SQBC Joint Conference, Mont Sainte-Anne, Quebec,
CanadaBy Dr. Wilson Shcolnik, Md, PhD Brazilian Society of Clinical Laboratory-Laboratory Medicine (SBPC/ML)

I am grateful for the opportunity to have participated in the event held by the Canadian Society ofClinical Chemists, through the IFCC-ABBOTT Visiting lecturer Program (VLP). I have no doubts about
the great value brought by this Program, both for the lecturers and the event participants.
My participation enabled an intense exchange of experiences with professionals who work in
Canadian laboratories and teachers who participated in the event.
Among the topics discussed with Canadian professionals I can mention: knowledge of the
scenario regarding laboratory services offered in Canada, including infrastructure, characteristics,
professionals’ performance, challenges and opportunities for improvement.
The main activities carried out were:
Symposium on IFCC Expert Insights on Quality Improvement in Laboratory Medicine and Patient
Safety;Consensus Group meeting and industry presentations;
Scientific Workshops: QIs in POCT;
Consensus group meeting conclusion and next steps.
The objectives of my participation were to provide participants with learning about:
1. The Brazilian clinical laboratories and the health system.
2. Existing regulatory requirements (which include structuring a quality system).
3. The clinical laboratories adherence to accreditation and laboratory indicators programs, as well as
the results obtained.
4. The history, initiatives and difficulties faced by the Brazilian Program of Laboratory Quality
Indicators
5. The details about the data platform and participation statistics of Brazilian and foreignlaboratories
6. The experiences and insights presented, so that they can be used in programs in other countries
The subjects discussed in the Consensus Group Meeting were:
1. Selection of smaller set of mandatory Quality Indicators to maximize participation and improve
patients’ safety at the international.
2. Increasing the number of laboratories in the calculation of Quality Specifications by developing a
new strategy of global Quality Specifications (Addition of national QS weighted based on the numberof labs included).
3. Increasing collaboration with industry to increase the number of software/middleware thatfacilitate access to the IFCC QIs.
4. Discussing the limitation of the number of laboratories participating in the MQI platform.
Discussing the value of potential decentralization by collaborating more closely with nationalsocieties and national programs.
5. Integration of QIs in POCT into the MQI guidelines.
6. Discussing the value and potential strategies to collaborate more closely with accreditation bodies
for a more formal integration of IFCC QIs into national recommendations.
7. Integration of QIs from other laboratory specialties.

Article continued on the next page

15

IFCC-Abbott Visiting Lecturer Program (VLP)
2024 CSCC / SQBC Joint Conference,Mont Sainte-Anne, Quebec, Canada

Soon the event coordinator, Prof. Vincent de Guire will submit to participants a publication proposalthat must also be evaluated and approved by Chair Prof Mario Plebani. The next step will be to makethe conclusions and recommendations of the WG LEPS public, through publication by the IFCC. The
WG will hold bimonthly meetings via videoconference.
The organization and logistics deserve praise. Everything worked perfectly and I had full assistancefrom the organization, both the Canadian Society and the IFCC.

Dr Wilson Shcolnik during his presentation

Dr Wilson Shcolnik, IFCC Abbott VLP (4th from theleft) with the Scientific Organizers of the 2024 CSCC/ SQBC Joint Conference in Mont Sainte-Anne,
Quebec (Canada)

16

IFCC-Abbott Visiting Lecturer Programme - V Jornadas
Científicas Julias - V Jornadas Internacionales 2024,
La Paz, Bolivia
By Beatriz Varela Asociación Bioquímica Uruguaya (ABU)

Introduction:
The congress was hosted by the Sociedad Boliviana de Bioquímica Clínica, filial La Paz, and was heldat the Real Plaza Hotel and Convention Center in La Paz.
A total of approximately 100 registrants attended the congress. One hall was used throughout thecongress, which was comfortable and very well equipped with modern audiovisual facilities.
Scientific Programme:
The academic program of the congress includes lectures by experts. A wide range of laboratory andclinical topics were included from all branches of laboratory medicine.
A total of 4 posters were presented and defended in person by the authors.
My contribution to the event was giving three 45-minute conferences. The conferences were titled:
1) Navigating the transition: strategies for managing quality control lot changes
2) Delta check: an analytical approach3) Risk Management in the Clinical Laboratory.
Also, I participated as part of the poster evaluation committee along with Dra Montserrat Blanes and
Dr Carlos Peruzzetto.
w
There was one social event, the welcome cocktail, during the congress, on the Thursday:
All the information provided prior to and during the congress was extremely clear and in a timely
manner.
My stay was exceptional, and the support provided to me was outstanding. In particular, I wish toacknowledge the friendship and assistance of Dra Fabiola Linares.

Poster evaluation panel members (L-R): dr Montserrat Blanes,

Poster certificate ceremony: the winners with the evaluation

Dr Carlos Peruzzetto, Dr Beatriz Varela.

panel members.

17

IFCC: the people
Interview with Prof. Dr. Tomris Ozben, IFCC President

Prof. Dra. Tomris
Ozben
IFCC President

Dr. BQF. María PasquelMoxley
C-PR/CPD-IFCC Chair
Member WG-IANT/RIA/
CPD-IFCC Interviewer

Dear Prof. Dr. Tomris Ozben, we kindly request a short interview for our readers.
1.- You have been active in IFCC for many years, you have participated in different andimportant positions, now that you are the IFCC President, what is your main objective for themost important World Federation of Laboratory Medicine such as the IFCC?
I am deeply honored and extend my heartfelt gratitude to the IFCC member societies across the 6
IFCC Regional Federations for their kind support and trust in electing me as the IFCC President for
the term 2024-2026. I genuinely appreciate their confidence and wish to reassure them that I am
wholeheartedly committed to deserving their trust. Assuming the role of President of the IFCC is
not only an immense privilege, but also a significant responsibility for me. I am enthusiastic about
the opportunities and challenges that lie ahead as I commence my journey of serving the IFCC
community, beginning my term on January 1st, 2024.
I am dedicated to investing my time, expertise, knowledge, and effort into sustaining, improving,and enhancing the functions, activities, and financial stability of the IFCC on a daily basis, for the
benefit of the IFCC, its Regional Federations, and member societies. It is my goal to address theireducational, scientific, and financial needs and to advocate on their behalf within the IFCC Executive
Board.
Assuming a leadership role alongside other committed members of the IFCC Executive Board, IFCC
officers, and the IFCC community, our shared mission is to fortify the robust foundation upon which
the Federation stands. Our objective is not merely to maintain, but to elevate IFCC functions andinitiatives, making significant contributions to the advancement of Laboratory Medicine and thedevelopment of its professionals. We are dedicated to identifying new opportunities and devising
innovative strategies that empower Laboratory Medicine to play an indispensable role in patientcare. Our aim is to ensure that the IFCC remains the foremost global organization representing
Laboratory Medicine worldwide.

Article continued on the next page18

Interview with
Prof. Dr. Tomris Ozben

We are set to raise the IFCC banner even higher, maintaining past initiatives while introducing novel
new projects. The combined expertise, knowledge, and fresh ideas from IFCC officers, coupled with
their enthusiastic contributions across various functional units, will drive us forward. We underscorethe importance of close collaboration with IFCC Regional Federations, IFCC Member Societies, andCorporate Members, encouraging their active engagement in all IFCC activities.
I firmly believe that advancing healthcare through Laboratory Medicine relies on the active
participation and committed involvement of IFCC Members and officers. Our collective efforts playa pivotal role in steering our profession toward the objectives and direction outlined in the new
IFCC Strategic Action Plans, set for implementation in the coming years. These plans have been
meticulously developed in collaboration with the IFCC Executive Board, IFCC Functional Units, IFCC
National Societies, and Corporate Members, incorporating their invaluable insights, ideas, andfeedback in formulating the IFCC Strategic Action Plans. This inclusive approach ensures that the
IFCC Strategic Action Plans authentically reflect the diverse perspectives and expertise within ourcommunity.
2.- There are many young scientists around the world who are part of the 6 Federations thatmake up the IFCC, what message do you send to them to be part of the IFCC organization?
I strongly encourage young scientists to actively engage and assume fundamental roles in IFCC
activities. Young Scientists (YSs) represent the future of Laboratory Medicine and constitute theprimary workforce of laboratory professionals. Our profession, Laboratory Medicine, is characterizedby constant evolution and dynamism. Young Scientists are the future leaders, but they require
training and encouragement to succeed in their roles, ideally with the support of experienced
leaders. To facilitate this, YSs must have access to activities that promote their participation, provide
training opportunities, and enhance communication and networking. In pursuit of these objectives, I
proposed the establishment of the IFCC Young Scientist FORUM to the IFCC Executive Board (EB) in
2019, which was graciously approved.
One of the primary goals of the IFCC YS FORUM is to facilitate the establishment of professional andscientific connections among YSs worldwide. The Scientific Program of the YS FORUMS is developed
and curated by young scientists through their IFCC Task Force-Young Scientists (TF-YS), creating an
ideal environment for YSs to exchange experiences, learn from peers, and stay informed about TF-YS
activities, opportunities, and challenges, thereby enhancing networking. It offers young scientists an
exceptional platform for open discussions, sharing scientific and research experiences, exchanging
ideas, initiating joint projects, arranging laboratory visits, and forming new professional and scientificconnections. All participating Young Scientists benefit from skill development for their careers while
engaging with ongoing TF-YS activities and networking opportunities.
Subsequent to the FORUM, all YSs attend the EuroMedLab/WorldLab Congresses, benefiting from an
outstanding scientific program comprising plenary lectures, symposia, and educational workshops
presented by eminent speakers showcasing the latest scientific advancements across Laboratory
Medicine disciplines. This presents an excellent opportunity for FORUM participants to interact withsenior officers and expert scientists in Laboratory Medicine. Additionally, attending the exhibition
allows FORUM participants to explore recent technological innovations and practical solutions
tailored to the needs of clinical laboratories.
The 3rd Edition of the IFCC FORUM For Young Scientists was held on May 26th, 2024, in Dubai,
United Arab Emirates. This event was a valuable platform for young scientists to further theirprofessional development and expand their networks.

Article continued on the next page

19

Interview with
Prof. Dr. Tomris Ozben

3.- In your personal and professional life, what does the IFCC represent to you?
IFCC holds a significant place in my life, serving as the focal point, especially since assuming
the role of its President. I dedicate a considerable amount of time to IFCC, often prioritizing itover my personal commitments to my family and friends. Day and night, I devote myself to IFCC,
brainstorming new projects aimed at benefiting IFCC and its members.
The following services have been instrumental in my acclimatization to the inner work of IFCC,
allowing me to familiarize myself with the activities of various IFCC functional units and therelationships between IFCC and its Regional Federations and member societies. They have provided
me with the opportunity to personally connect with numerous colleagues all around the world. Forme, this is the greatest joy and advantage - knowing and collaborating with so many esteemed
colleagues and friends worldwide.
Throughout my journey with IFCC, I have had the privilege of serving in various capacities:
•
•
•

•
•
•

I initiated my service to IFCC as the Corresponding Member (2002-2004), Full Member (2005-2007)
and two terms as the Chair (2008-2014) of the Congresses and Conferences Committee (C-CC).
I was elected by the IFCC Council and served two terms as the IFCC Treasurer (2015-2017 and2018-2020).
I am one of the five members of the Board of Directors of the IFCC Foundation for Emerging
Nations (FEN), a non-profit Charitable Trust dedicated to enhancing the quality and accessibilityof laboratory medicine services, particularly in emerging nations (2016-present).
I initiated to establish and serve as the IFCC YS FORUM Consultant (2020-present).
I have served as the Organising / Scientific Committee Member for numerous IFCC EuroMedLaband WorldLab Congresses and IFCC General Conferences.
I was elected by the IFCC Council to serve as the IFCC President-Elect (2023), IFCC President(2024-2025-2026) and IFCC Past-President (2027-2028).

These experiences have provided me with invaluable insights and connections within the global
Laboratory Medicine community, allowing me to contribute meaningfully to the advancement of ourfield.
4.- A final message that you would like to add for all our readers?
Success in this evolving landscape requires collaborations among industry, public, private, andacademic entities driving innovation. Achieving our shared objectives demands concerted action andcooperation.
I extend a warm invitation to the entire IFCC community to actively engage in IFCC’s initiatives,
fostering collaboration to strengthen IFCC’s leadership in advancing laboratory medicine, integrated
diagnostics, and elevating healthcare and medical laboratories’ quality globally. Your involvement
and contributions are essential as we collectively work towards these common goals. Your feedback,participation, and engagement will play a crucial role in steering laboratory medicine forward andshaping the future of our profession.
In recent years, IFCC’s activities have seen consistent growth, with its substantial contributions
to enhancing Laboratory Medicine widely recognized. This remarkable success is owed to thevoluntary service, dedication, and time generously given by over 700 laboratory scientists from
Member Societies and Corporate Members, serving across various IFCC Functional Units. I extend
my heartfelt gratitude to the IFCC officers representing Member Societies and Corporate Members
for their continuous support over the years. Their enduring commitment and loyalty have played apivotal role in the successful execution of numerous IFCC tasks and projects.

Article continued on the next page

20

Interview with
Prof. Dr. Tomris Ozben

I am looking forward to fostering productive cooperation with IFCC Executive Board members andofficers, establishing collaborations and effective bridges with IFCC Regional Federations, National
Societies, and Corporate Members in the ongoing and future activities of IFCC.
Dear Prof. Tomris Ozben, we thank you very much for the valuable time you have dedicated toanswering this interview.

21

22

IFCC Calls for Nominations
Participate into IFCC activities and give your contribution! Review the open positions and, if
interested, contact your National or Corporate Representative. Currently following call for nomination
are open:
New IFCC Committees:••on Molecular Diagnostics in Infectious Diseases (C-MDID): with focus on tuberculosis
diagnosis and antimicrobial resistance testing.
on Molecular Diagnostics in Oncology (C-MDO): with focus on improving accuracy ofmolecular diagnostic methods for circulating tumour cells and circulating tumour DNA forthe diagnosis and management of malignant diseases.

The Call for Nomination is for 5 Members (1 Chair and 4 Members) for both Committees.
Nominations for all positions have to be sent to IFCC Office (elisa.fossati@ifcc.org)
before September 10th, 2024.

23

IFCC: the Young Scientists
IFCC WorldLab 2024 – Dubai through Young Scientists’ Eyes
Part 2Mia Jade Gruzin
University of New South Wales, Sydney – Australia
As my first international conference, it was incredibly rewarding toconnect with scientists, researchers and clinicians at various stagesof their careers from across the world. Despite the diverse contexts
in which we work and study, I was surprised to see how similar ourissues and barriers are. Engaging in discussions about these common
challenges was incredibly enlightening, and it was a pleasure to build
new connections and explore potential research collaborations that I
hope to maintain for years to come.

Naila Hasanova
Azerbaijan Scientific Research institute of Traumatology andOrthopedics
I wanted to attend the congress. It finally happened with the support of
IFCC. It was an incredibly beautiful and magnificent congress. It was very
efficient. It allowed me to learn something new from the presentations.
The Young Scientists Forum was a success. Successful presentations
were made in the workshops. I was also happy to present my own
poster in the exhibition hall and to see it published in the Clinica Chimica
Acta journal.
I met people from different countries and many researchers at thecongress. This was very special for me. It was encouraging to meetfamous scientists at the congress. I will always remember it fondly as
the first congress I attended abroad. I wish to attend IFCC congresses
every year.

Li Wendi
Department of Clinical Laboratory, State Key Laboratory of Molecular
Oncology, National Cancer Center/National Clinical Research, Beijing,
China.
This was my first time attending an international conference, and I was
excited to see so many new faces. During the IFCC FORUM for Young
Scientists on the 25th, I met a new friend, Mario from Malaysia. She
is a delightful person, and we had extensive discussions. She has akeen interest in artificial intelligence and big data, and we exchanged
our thoughts on related research topics. On the 26th, I presented
my research in the poster exhibition area to scientists from various
countries, who expressed great interest in my work. On the 28th, I
had the great honor of meeting Mrs. Tomris, the IFCC President, whoawarded certificates to all scholarship recipients. I was pleasantly
surprised to discover that I was the only female young scientist from
China to receive the scholarship, which made me immensely proud.

Article continued on the next page24

Dubai through Young
Scientists’ Eyes

Rayan Suliman
Institute for Clinical Chemistry and Laboratory Medicine, University
Hospital Dresden, Dresden, Germany
As a young specialist in Laboratory Medicine, I had the privilege ofparticipating in the Forum for Young Scientists on 25 May. This event
provided a unique platform for knowledge exchange and networking,where young researchers presented their work on a wide range of topics
Attending the subsequent days of the IFCC WorldLab was also anenriching experience. Engaging with influential researchers andrenowned clinical chemists fueled my passion for advancing laboratory
medicine. The IFCC WorldLab 2024 was more than just an academic
event. As I reflect on those days, I am more committed to advancing
clinical laboratory medicine and contributing to our collective knowledge.
I eagerly look forward to the next IFCC Congress in Brussels next year.

Laura Valina Amado
Laboratory Medicine Department - Hospital Universitari Son Espases Palma, Spain
The YS Forum is a fantastic idea for starting the WL Congress, since it
provides a chance for young people attending this event to meet eachother and share knowledge, ideas and opinions.
We had the chance to exchange cultural experiences, regarding people
from many distant countries got together.
I deeply encourage young scientists to apply for IFCC Travel
Scholarships to attend these events. Getting involved with other
Clinicals and Researchers is somehow mandatory for developping agood network that will allow clinical needs and advances to be sharedand, utmost importance, understood recognised and spread. On ourdaily base, we tend to focus in the needs of our community, which may
highly differ from those in other parts of the world. These events give us
all perspective and humbleness, as well as help us better understand
not only science, but societies and the world.

Tara Rolić
Osijek University Hospital Centre, Institute of Laboratory Diagnostics,
Faculty of Medicine, University of Osijek, Osijek, Croatia
I was truly honored and excited to participate in the 3rd IFCC Forumfor Young Scientists and WorldLab in Dubai, UAE thanks to the IFCC
scholarship! I had an amazing opportunity to present my work from an
IFCC Professional Exchange Program which was conducted at University
Hospital Oslo, Norway, where I focused on calculating reference intervals
for thyroid hormones using an indirect approach. It was great to discuss
my results with colleagues from around the world. I loved reconnectingwith friends and colleagues. It’s hard to pick a favorite moment, but
I especially appreciated the interactive sessions on leadership andmanagement alongside the regular scientific and professional topics.
This is the way forward for young scientists! Congratulations and thankyou to everyone involved!

Article continued on the next page25

Dubai through Young
Scientists’ Eyes

Francis Kiigu Wathigo
The Nairobi Hospital, Argwings-Kodhek Road, Nairobi, Kenya.
It was great privilege to attend and participate in the 3rd edition of the
IFCC Forum for Young Scientists and XXVI IFCC WorldLab Conference
2024 in Dubai.
The conference had stimulating presentations with thought provoking
discussions and insightful ideas. I was particularly impressed withdiscussions around evolution in assessment of renal dysfunction as well
as new approaches in diagnosis of neurodegenerative diseases. It was
indeed a wonderful learning experience.
It was also great opportunity to meet and network with peers as wellas mentors and look forward to collaborative efforts in research. I lookforward to participating in the 26th IFCC-EFLM EuroMedLab congress ofclinical chemistry and laboratory medicine 2025 in Brussels.
Attending this conference was an invaluable experience, allowing me toengage with the brightest minds in laboratory science.

Sana Yaacoub
University of the Holy Spirit Kaslik (USEK), Faculty of Medicine andMedical Sciences, Jounieh, Lebanon
Thank you for the scholarship. I was able to join the Young Scientists
Forum at the Conrad Hotel, where I had the privilege of meeting
experts from different countries. The IFCC World Lab Congress at
the Dubai World Trade Center surpassed all expectations. The levelof organization, presentations, and exhibitions was exceptional. The
symposia were particularly engaging, offering valuable insights andlearning opportunities. Participating in workshops and discussions
reinforced the importance of collaboration and sharing expertise indriving innovation.
Presenting my poster during the Young Scientists Poster Tour was ahighlight, fostering educational discussions with peers.

Stephanie El Hawat
Centre Hospitalier Notre Dame Des Secours, Byblos, Lebanon
The FORUM was really a cultural phenomenon joining all these people
with amazing backgrounds in one place. I also got to attend the IFCC
world lab Congress: words felt short when trying to describe this event.
From the organization to the presentation to the exhibition everything
was more than perfect. I was fortunate enough to participate in several
workshops and panel discussions where experts shared their insighton how working together can lead to groundbreaking innovations. I
also had the opportunity to present my poster at the young scientist’s
poster tour presentation. It was very educational on so many levels andwe were in small groups discussing each other’s presentation with thejury. I came back to Lebanon and I am now more than ever determined toamplify my academic work and research activity in this field.

Article continued on the next page26

Dubai through Young
Scientists’ Eyes

Tamer Ibrahim Shabaneh
Hebron-West bank – Palestine
Participation in young scientists forum, IFCC WorldLab lectures,workshops and poster sessions: to be honest it is first time for me
to participate in a global conference especially with these minds inyoung scientists, and in first day: It was a great day, starts with thefirst meeting to young scientists members, so honor to be part of themand they surprise me with all motivation and the mind of the young
members. At the opening lecture I was a little shocked about Professor
Dennis Lo, he is a special person: he is the person found cfDNA inmaternal serum, and then I know I’m in a something massive, something
different.

More comments were made by
Mariam Kvezereli
Department of Immunology, Tbilisi State Medical University, Tbilisi, Georgia
The FORUM for Young Scientists provided an opportunity for networking and exchanging ideas
with fellow young professionals from all over the world. The inspiration and motivation I gained frominteracting with my peers have reinvigorated my passion for continuous learning and innovation.
This experience has prompted me to advocate for more workshops and seminars within our National
Society to share the knowledge and advancements in the field of neurology lab diagnostics.
Furthermore, the congress highlighted the importance of international collaboration. I am now morecommitted to seeking partnerships with other national societies and international organizations toparticipate in joint research projects and knowledge exchange programs.
Aristea Milona
Attikon University Hospital, Rimini 1, Chaidari, Athens, Greece
It was a great honor for me to participate in the IFCC Forum for young Scientists in Dubai. This
international meeting was an experience that I will never forget. It was my first international event.
I haven’t had the opportunity before to interact with so many professionals from all over the world.
So, this experience gave me a lot of valuable scientific information in the field of clinical biochemistry.
Nevertheless, I had also the opportunity to come closer to the rich Arabic culture and at the sametime to one of the most modern cities in the world. It was nice to meet and socialize with so many
young scientists from all over the world.
Anjali Sudha
Department of Biochemistry, All India Institute of Medical Sciences - Jodhpur, India
The knowledge and insights gained during the conference have broadened my understanding of
the scientific landscape, reigniting my passion for advancing the boundaries of knowledge. The
discussions on key breakthroughs in Clinical Chemistry and their applications in Medical Laboratory
practices were particularly enlightening. I am eager to share these insights with my colleagues andexplore innovative ideas that can be applied in healthcare. The topics covered during the sessions
will help me better understand important advancements, allowing me to initiate applicable ideas forinnovations in the healthcare sector.

27

Contribute to IFCC eNews
Twelve Integrated Clinical Care Teams Receiving
Recognition Through the UNIVANTS of Healthcare
Excellence Awards

Driving change in healthcare is neither easy, nor quick. Measuring that change is often equallyas hard. With this in mind, the UNIVANTS of Healthcare Excellence award program seeks torecognize, amplify and replicate best practices in healthcare that are led by integrated clinical careteams across the globe. In 2024, the UNIVANTS program is proud to recognize the brilliant work of
twelve clinical care teams who have not only unified across the care continuum, but have made ameasurable impact for patients, clinicians, health systems/administrations and payors.
These twelve best practices have made measurably improved care, with impact made acrossdisease states and focuses, including closing care gaps, enhancing equity, improving women’s
health, enabling access to care, improving safety, and more. With 3 top global winners, 3 teams of
distinction, and 6 teams of achievement (see table below), these diverse and innovative initiatives
span geographies, health systems, patients and disease states. To learn more about these bestpractices, please visit www.UnivantsHCE.com.
Are you interested in recognition through UNIVANTS? Start preparing your application now asapplications for the 2025 UNIVANTS of Healthcare Excellence award program open Aug 1, 2024,
through until Nov 15, 2024. To learn more about UNIVANTS, to gain insights on tips and tricks and/or
apply, please visit www.UnivantsHCE.com.
The UNIVANTS of Healthcare Excellence award program is proudly comprised of the following
program partners: International Federation of Clinical Chemistry (IFCC), Association for Diagnostics
and Laboratory Medicine (ADLM, formerly AACC), Modern Healthcare, National Association for
Healthcare Quality (NAHQ), European Health Management Association (EHMA), Institute of Health
Economics (IHE), Healthcare Information and Management Systems Society (HIMSS); each inpartnership with Abbott.

Article continued on the next page28

Twelve Integrated Clinical Care Teams Receiving
Recognition Through the UNIVANTS of Healthcare
Excellence Awards

UNIVANTS OF HEALTHCARE EXCELLENCE TOP ELITE WINNERS
GetCheckedOnline: Better access to testing for sexually-transmitted
and blood-borne infections
British Columbia Centre for Disease Control

Devon Haag
Meghan McLennan

Mark Gilbert
Susie van der Valk

Garth Graham

Early detection of metabolic-dysfunction associated steatotic liver disease using FIB-4
Premier Integrated Labs Sdn Bhd

Yoke Lee Low
Hareeff Muhammed

Improved management of patients with high LDL-C through electronic health recorddirected algorithms for guideline-concordant high-intensity statin prescribing
Kaiser Permanente Southern California

Leslie Charles Lai Chin Loy
Mun Yee, Evonne Kong

Matthew Mefford

Kristi Reynolds

Michael Kanter

Tracy Imley

Ronald Scott

UNIVANTS OF HEALTHCARE EXCELLENCE RECOGNITION OF DISTINCTION
Improving equity in maternal and newborn outcomes by eliminating disparities in maternal
drug screening
Washington University School of Medicine, Barnes-Jewish Hospital,
and St. Louis Children’s Hospital
Improving access to health services in vulnerable communities affected by war
EsculabVahid Azimi

Noor Riaz

Jeannie Kelly

Stephen Roper

Lauren Nacke

Viktoriia Honcharenko

Liudmyla Kostiuk

Anna Konyk

Iryna Mandzyuk

Olena Yanchinska

Improved patient outcomes facilitated by c-peptide testing, enabling reclassificationand therapeutic changes for patients with diabetes
University Hospital of Wales

Arshiya Tabasum
Colin Dayan

Carol Evans
Julia Johansson Evans

Rowan Hellier

UNIVANTS OF HEALTHCARE EXCELLENCE RECOGNITION OF ACHIEVEMENT
Reducing unnecessary CT scans in the emergency department with new mild head injury
assessment pathway
Klinikum Lüneburg
The Kansas Two-Step: Simplifying the diagnosis of clostridioides difficile at an academic
medical center
The University of Kansas Health System
No time to lose with lives on the line - Maximizing efficiency in the lab to save more lives
through organ donation
Southwest Transplant Alliance
The Women and Heart Program - Empowering women’s health through early
identification and prevention of coronary risk
Institute for Cardiovascular Prevention and Rehabilitation
Reducing unnecessary admissions associated with pediatric mononucleosis via
implementation of EBV IgM testing in the emergency department
Emergency Clinical County Hospital Targu Mures
Establishment of a monomer prolactin detection method and specific reference interval
to enhance the ability to identify macroprolactinemia
Huashan Hospital Fudan University

Felix Brüning-Wolter

Thomas Rodt

Meike Schrader

Jörg Cramer

Nicola Wolff
Matthew Loeb

Matt Shoemaker

Matt Humphrey

Maggie Reavis

Sarah Mester
Selena Warden

Reid Freeman

Doug Butler

Cristina Solomon

Sean Forquer
Andrea Snagić

Ante Miljak

Goran Krstačić

Sonja Frančula-Zaninović

Oana Roxana Oprea
Karoly Vecsei

Lucia Mezei
Dobreanu Minodora

Florina Floristeanu
Ming Guan
Yao HuZhaoyun Zhang
Yao Zhao

Hongying Ye

ADD-149724-GBL-EN

29

DON’T MISS OUT…

ACT NOW!

The UNIVANTS of Healthcare Excellence Award
recognizes teams who collaborate across disciplines andtransform healthcare delivery, and ultimately patient lives.
Submit your team application to the UNIVANTS of
Healthcare Excellence Award program on or before
November 15th at UnivantsHCE.com.
The time is now to highlight your healthcare excellence!

© 2023 Abbott. All rights reserved. ADD-132526-GBL-EN.

30

Impact of luminescence in Clinical Laboratories
by Dr. Luis Figueroa Montes President of AMPPC, PerúORCID https://orcid.org/0000-0002-3708-8603

I am going to tell you a story, where one of the protagonists ofluminescence obtained the Nobel Prize in Biochemistry in 2008. The
Americans Martin Chalfie, Roger Tsien and the Japanese Osamu
Shimomura, together obtained the Nobel Prize in Chemistry in 2008 “Fordiscovery and development of green fluorescent protein. This protein(Green Fluorescent Protein – GFP) was observed for the first time in thejellyfish Aequorea victoria in 1962. Today it is one of the most used tools
in biomedicine (1).
This jellyfish lives off the west coast of North America. GPF resides in its
light-emitting organs, which glows intensely under light ultraviolet. GFP
revolutionized biological sciences. Its green light allows scientists to track, among other things,
cancerous tumors, new blood vessels, how Alzheimer’s disease kills brain neurons, how cells infectedby the human immunodeficiency virus replicate, understand how neurons are organized within of thebrain and how proteins interact within the cell (2).
In this article we will highlight the contribution of the Japanese Osamu Shimomura. A scientist who
knew him closely says that he witnessed the explosion of the Nagasaki atomic bomb in August 1945,
just 15 kilometers from the epicenter, when he was a teenager and worked in an aircraft repair shop.
These memories are a fundamental part of the story of this boy born in Kyoto who grew up in one of
the most difficult eras in Japanese history and later identified a fluorescent substance in a jellyfish
that, years later, would forever illuminate the field of biology (3).
Shimomura moves around his Marine Biology Laboratory in Woods Hole, Massachusetts, as if
carrying his own force field. His lean face with its benevolent expression has at the same timesomething monastic, academic and iron (like a Jedi). He guides me through the small, cramped room,
equipped with the latest in electron microscopy, and stops before a shelf with a glass bottle thatsays “Cypridina 1944” (3).
He takes a handful of tiny, dried crustaceans (similar to sesame seeds), puts them in a mortar, adds
drops of water, and grinds them. Soon a soft light blue luminescence emerges that intensifies whenpressure is applied “I have performed this demonstration many times and I am always amazed to seethat the glow continues to appear after so many years of these small organisms being dissected” (3).
The first time Shimomura saw bioluminescence he was 27 years old; he had just graduated as apharmacist and had just accepted a position as assistant to Professor Yoshimasa Hirata, at Nagoya
University (3). Hirata was dedicated to isolating and purifying natural compounds. “We don’t know
anything about this,” the professor told his new assistant, showing her the light of the organism
Cypridina hilgendorfii. “”Only it glows.” Are you interested in finding out why?” Bioluminescence has
fascinated scientists for centuries. In 1887, Raphael Dubois, from the University of Lyon in France,
had discovered that this light of animal origin (bioluminescence)
appears thanks to two substances: one that acts as fuel and another that is the igniter (3). Dubois
isolated these 2 components and named them luciferin (the fuel) and luciferase (the catalyst, thesubstance that precipitates the chemical reaction), alluding to the name Lucifer, which means“bringer of light” (3).
Bioluminescence is a rare characteristic in terrestrial animals, but very common in marine beings. In
the depths of the ocean live bacteria, protozoa, fungi, jellyfish, squid, worms, crustaceans, mollusks
and sharks that have the ability to produce light in a chemical reaction so effective that it barely
releases heat; a cold light that can serve as an alarm signal, an escapist’s disguise, an object ofseduction and a bluff to find food (3).

Article continued on the next page31

Impact of luminescencein Clinical Laboratories

Shimomura, accidentally trying to make luciferin crystals from Cypridina, brought the luciferin into
contact with an acidic medium. The next day he saw with amazement that small red crystals had
formed on the surface of the solution. They were pure luciferin crystals, the product of contact withacid. The luminosity of the crystals turned out to be 37,000 times greater than the dry powder of thecrustacean (3). This serendipitous discovery gave Shimomura the tools to establish the exact natureof Cypridina’s luciferin. News of his feat reached Princeton University, where Frank Johnson had triedin vain to do the same. Frustrated with his own attempts, Johnson invited the young Japanese to
move to the United States to work on what would be his great contribution to science (3).
Once with Shimomura in the US, Johnson turned off the lights, gave him a bottle of whitish powder
and mixed it with water. But, unlike the experience with Cypridina, there was no light reaction. “This isdust from the bioluminescent jellyfish Aequorea Victoria.” Its effect only lasts a few hours while it isfresh and cannot be reactivated. Would you be interested in studying this jellyfish?” Johnson asked
the new collaborator. The same afternoon of their arrival they began collecting jellyfish on the pierof the laboratories of the University of Washington using nets to clean pools. During the summer of1961 they collected and squeezed more than 9,000 jellyfish (3).
One afternoon, when he was cleaning the glass containers after a session of experiments,
Shimomura poured into the sink some of the jellyfish juice whose pH had been neutralized so that itwas neither acidic nor basic. When the liquid made contact with the sink, he released a bright flashof blue light. After a while, he realized that the activating ingredient was calcium from seawater. If
calcium was able to ignite the reaction, then extracting it would surely inhibit it (3).
In an article published in 1962 by Shimomura and collaborators, they observed that green lightemanates from the intact light cells of the animal. The phenomenon of absorbing light of one
color and remitting it of another is called fluorescence and the molecule that Shimomura and his
collaborators mention today is called green fluorescent protein (4).
In this way, Shimomura, since the Nobel Prize, his life has become a parade of conferences,interviews and explanations to the press. At one of those conferences, she was asked why she
ended up pulling jellyfish out of the water that summer in Washington. Shimomura responded: “Tosolve a mystery” (3).

Osamu Shimomura (left) receiving his Nobel medal in 2008. He
was one of three sharing the prize in chemistry. Photo by AP
photo/Scanpix Sweden, Anders Wiklund

Article continued on the next page32

Impact of luminescencein Clinical Laboratories

Currently, luminescence has many applications. Defined as the emission of light that is not caused
by a high temperature (cold light). There are many light-emitting processes around us. They are
produced naturally or artificially. Examples of natural luminescence are fireflies and phytoplankton:
bioluminescence, or artificial luminescence by light-emitting diodes and computer monitors:
electroluminescence (5).
There are different types of luminescence depending on the method of generating the high-energy
substance, such as chemiluminescence, photoluminescence, electro chemiluminescence andradioluminescence. In addition, there are types of luminescence depending on the duration of thesignal emission, such as flash and glow luminescence (6).
Currently, according to my understanding, more than 70% of the world’s clinical laboratories on
different continents use automated instruments that use luminescence in its various forms, for the
analytical process of different biomarkers that are used in diagnosis and monitoring of chronic andinfectious diseases. Many contributions to our daily lives were made by people who gave years of
their lives, discovering the “Mysteries of science”, such as the Japanese scientist Osamu Shimomura.

Sources: https://www.embl.org/about/info/
communications/blog/2021/05/osamu-shimomura/

33

News from Regional Federations and Member
Societies
Uniting Visionaries: Reflections on the 4th Annual Congressof the Nepalese Association for Clinical Chemistry
1. Dr. Vivek Pant, Corresponding Member, Task Force Young Scientist, IFCC andCorresponding Member, Communication and Publication Committee, APFCB
2. Dr. Santosh Pradhan , Corresponding Member, Task Force on Ethics, IFCC

After the postponement of four years, the Nepalese Association for Clinical Chemistry (NACC) had
the pleasure to organize the 4th annual congress with the theme “Current and Emerging Trends inClinical Chemistry” on April 27th 2024 at KIST Medical College and Teaching Hospital, Kathmandu.
This theme was carefully chosen to reflect the evolving landscape of clinical chemistry.
Nearly 125 participants attended the Congress, which was divided into opening session, scientificsession and election for new executive body. Apart from this, few industrial workshops and subgroup discussion were also held. Pre-congress program included finalizing two survey questionnaire
for the congress participants, one dedicated to laboratory professional and physician interaction
and next related to the ethics in clinical laboratory. We were excited to have our face-to face meeting
after a long gap.
Registration
During this annual conference, there was a slightly different approach taken with the process ofregistration. We created a social media (Whatsapp) group and suggested all laboratory professionals
to register themselves and add other professionals in this dedicated group to motivate them forregistration. Eventually, a room full of attendees counting 125 in number participating from many
parts of the country participated in the congress. The greatest satisfaction has been to witness the
emergence of the new generation within our organization.
Opening Session
Initially there was an appreciation of the long services that have been provided with past executive
committee. Many eminent personalities in the field of laboratory medicine within the county wereasked to speak few words about our profession and this professional society. All these activities help
to sustain and enrich our young minds.
Scientific Session
The first lecture was by Prof. Dr. Kun-Young Sohn from Trillium health partners, Canada on topic “Intra-operative monitoring of PTH/Adrenal venous sampling (AVS) for primary aldosteronism”. PTH
monitoring during surgery aids in the identification of parathyroid glands. Surgeons can assess theadequacy of parathyroid function and avoid inadvertent damage or removal. AVS is a specialized
procedure used to differentiate unilateral from bilateral adrenal disease. It involves sampling bloodfrom both adrenal veins to measure aldosterone and cortisol levels. This procedure helps localize
the source of aldosterone overproduction, guiding surgical intervention. The lecture delved into thetechniques involved in intra-operative PTH monitoring and AVS along with few cases encounteredby Dr. Sohn in his center. The lecture emphasized the importance of accurate interpretation of
results for optimal patient outcomes. Further research and clinical studies are warranted to explore
advancements in intra-operative monitoring techniques in Nepal.

Article continued on the next page34

Uniting Visionaries: Reflections on the
4th Annual Congress of the Nepalese
Association for Clinical Chemistry

The second lecture was to a concise update on need of newborn screening in Nepal. This lecture
was delivered by Dr. Bijaya Mishra , assistant professor from B.P Koirala Institute of Health Sciences,
Dharan, Nepal. The birth rate in Nepal as per 2023 is 18.377 births per 1000. Congenital malformationand genetic disorders are gradually replacing infectious cause of perinatal and neonatal mortality.
The infant mortality rate of Nepal in 2024 is 22.716 per 1000 birth. Nepal does not have a national
newborn screening program as part of its health policy. It is evident from our preliminary analysis
that the financial loss for the nation due to the preventable newborn disease is much higher thanthe overall expenditure for screening, diagnosis, and treatment. Dr. Mishra advocated that Nepal issuitable for initiating a Newborn Screening Program.
Newly elected Executive Body
The newly elected executive members in NACC have been entrusted with decision-making authority
and leadership responsibilities. Led by visionary leadership of Prof. Dr. Madhab Lamsal, the executive
body aims to steer the association towards greater heights of achievement and impact in the fieldof clinical chemistry. The collective vision of the body encompasses several key objectives such asenhancing professional development, promoting NACC journal, advocating for quality assurance,
strengthening collaboration and empowering next generation.
Surveys
Effective communication between laboratory professionals and physicians is crucial for accurate
diagnosis, proper patient care, and improved healthcare outcomes. In Nepal, where healthcare
infrastructure is developing rapidly, it’s imperative to assess the current state of communication
between these two vital components of the healthcare system. Serving both as a clinical resource
for the laboratory community and a laboratory resource for the clinical community has beenchallenging for most of us. To address this apparent gap, a survey was done among participants who
represented medical colleges, private and public laboratories throughout the country. Therefore thefirst survey was about laboratory professional and clinician interaction.
Nepal’s healthcare system is undergoing significant transformations, with advancements intechnology, increasing patient expectations, and evolving regulatory frameworks. However, theethical dimensions of laboratory medicine, including issues such as patient confidentiality, informed
consent, quality assurance, and professional conduct, are essential but often overlooked aspects.
Understanding the current ethical landscape is crucial for ensuring patient safety, maintaining
public trust, and upholding professional standards. Therefore the second survey was about ethics inlaboratory medicine. The final results for both surveys will be published shortly.
Finally, this congress provided ample opportunities for networking and collaboration among
attendees, fostering discussions and exchanges of ideas that are crucial for advancing the field ofclinical chemistry in Nepal and beyond.

Article continued on the next page

35

Uniting Visionaries: Reflections on the
4th Annual Congress of the Nepalese
Association for Clinical ChemistryProf. Dr. Kun-Young Sohn (L) provided certificate ofDr. Bijaya Mishra provided certificate of appreciation by Profappreciation by Prof Dr. Shyam Sundar Malla (R)Dr. Madhav Gautam (R)New NACC Executive Board (2024)
Back Row (Left to Right): Mr. Shravan Kumar Mishra (Member),

Front Row ( Left To Right): Dr. Bijaya Mishra (Member), Dr.

Mr. Raju Dube (Secretary), Dr. Vijay Kumar Sharma (Senior Vice

Ranjan Suwal (Member), Mr. Rakesh Pokhrel (Member), Dr.

President), Dr. Prabodh Risal (Vice President), Prof. Dr. Madhab

Ram Vinod Mahato (General Secretary), Mr. Santos Subedee

Lamsal (President), Dr. Binod Kumar Yadav (Member), Mr. Manoj(Member), Dr. Santosh Pradhan (Treasurer), Mr. Basanta Gelal

Sigdel (Member), Dr. Saroj Thapa (Member), Mr. Suman Sapkota(Member), Mr. Tapeshwor Yadav (Member), Dr. Bishal Raj Joshi(Member)(Member)36

26th IFCC-EFLM
EUROMEDLAB CONGRESS OF
CLINICAL CHEMISTRYAND LABORATORY MEDICINE
49th ANNUAL MEETING
OF THE ROYAL BELGIAN SOCIETY
OF LABORATORY MEDICINE

18 TO 22MAY 2025
FROM

VENUE

www.euromedlab2025brussels.org

Brussels Expo

15 January 2025
15 March 2025

Deadline for poster abstract submission
Deadline for reduced registration fees
37

IFCC’s Calendar of Congresses,
Conferences & Events
IFCC and Regional Federation
Events
Date

Title

Place

Oct 3 - 6,
2024

XXVI COLABIOCLI 2024

Cartagena,CO

Oct 31 - Nov 3,
2024

APFCB 2024 Sydney

Sidney,AU

May 18 - 22,
2025

XXVI IFCC-EFLM
EUROMEDLAB 2025

Brussels,BE

Oct 25 30, 2026

XXVII IFCC WORLDLAB 2026

New Dehli,IN

Oct 10 - 13,
2027

APFCB 2027 KUALA LUMPUR

Kuala
Lumpur, MY

Date to be
selected

XXVII IFCC-EFLM EUROMEDLAB
2027

Venue to be
selected

Date to be
selected

XXVII IFCC WORLDLAB 2028

Venue to be
selected

Date to be
selected

XXVII IFCC-EFLM EUROMEDLAB
2029

Venue to be
selected

Date to be
selected

XXVII IFCC WORLDLAB 2030

Venue to be
selected

Article continued on the next page38

Corporate Member Events with
IFCC Auspices
Date

Title

Place

Aug 26.
2024

International Symposium on
Laboratory Medicine
SNIBE

International
Academic
Hall, Snibe
Building-No.2
Shenzhen,
P.R. China

Nov 16,2024

Inter-QCTopics Internationalseminars on Quality Control:
Patient blood management –what is the role of the laboratory
according to ISO 15189?

Qualityconsulting
online event,HR

Sep 14,2024

Inter-QCTopics Internationalseminars on Quality Control :Laboratory screening for infectious
agents in blood services: methods
and quality control

Qualityconsulting
online event,
BR

Article continued on the next page39

Other events with
IFCC auspices
Click here40

Published ten times a year:

Advertise in
IFCC eNews!
Showcase your products and initiatives
to more than 51.000 laboratory medicine
specialists throughout Europe, North
America, Asia- Pacific, Middle East, Africa
and Latin America: laboratory directors,
clinical chemists, and other clinicallaboratory specialists and technologists,
leading manufacturers, distributors anddealers in the field.
• Ten issues per year
• Free-of-charge to readers• Interactive digital edition

No 1/2
No3
No 4
No5
No 6
No 7/8
No9
No 10
No 11
No 12

January/February
March
April
May
June
July/August
September
OctoberNovember
December

For prices, formats and any further information
on how your company can gain unique access\tointernational markets through advertsingwith IFCC, please email us at enews@ifcc.org.
IFCC Corporate Members receive a 25%
discount on current prices.

41

IFCC Executive Board 2024 - 2026

TomrisOZBEN
President

Khosrow
ADELI
Past-President

SergioBERNARDINI
SecretaryAlexander
HALIASSOS
Treasurer

TriciaRAVALICO
Corporate
Representative

T. BADRICK
Asia-Pacific Fed
for Clin Biochem
and Lab Med(APFCB)

M. PLEBANI
European Fed ofClin Chem andLab Medicine(EFLM)

E. FREGGIARO
Latin-American
Confederationof Clin
Biochemistry(COLABIOCLI)T. PILLAY (ZA)
Communications
andPublications
Division Chair

D. GRUSON (BE)
Emerging
Technologies
Division Chair

P. LAITINEN (FI)Congresses andConferences
Committee Chair

Regional Representatives

R. ERASMUS
AfricanFederation ofClinical Chemistry(AFCC)

O. NAJJAR
ArabFederation ofClinical Biology(AFCB)

D. GRENACHE
North American
Fed of Clin
Chem and Lab
Med(NAFCC)IFCC Divisions and C-CC Chairs

C. COBBAERT (NL)
Scientific
Division Chair

N. RIFAI (US)
Education andManagement
Division Chair

IFCC Office Staff(L-R) Elisa Fossati, Smeralda Skenderaj, Paola Bramati, Silvia Colli Lanzi, Silvia Cardinale

42

IFCC Membership
Full members

Albania (AL)
Algeria (DZ)
Argentina (AR)Armenia (AM)Australasia and New
Zealand (AU/NZ)
Austria (AT)Azerbaijan (AZ)
Belgium (BE)Bolivia (BO)
Bosnia Herzegovina (BA)
Brazil (BR)
Bulgaria (BG)
Canada (CA)Chile (CL)
China Beijing (CN)China Taipei (TW)
Colombia (CO)Croatia (HR)Cuba (CU)
Cyprus (CY)
Czech Republic (CZ)
Denmark (DK)
Dominican Rep (DO)
Ecuador (EC)Egypt (EG)Estonia (EE)
Ethiopia (ET)Finland (FI)France (FR)Georgia (GE)Germany (DE)Greece (GR)
Guatemala (GT)Hong Kong (HK)
Hungary (HU)
Iceland (IS)India (IN)Indonesia (ID)
Iran (IR)Iraq (IQ)
Ireland (IE)
Israel (IL)
Italy (IT)Japan (JP)Jordan (JO)
Kazakhstan (KZ)
Kenya (KE)
Korea (KR)Kosovo (XK)Corporate members

Latvia (LV)
Lebanon (LB)
Libya (LY)
Lithuania (LT)
Luxembourg (LU)
Malawi (MW)Malaysia (MY)Mexico (MX)Montenegro (ME)
Morocco (MA)
Myanmar (MM)
Nepal (NP)
Netherlands (NL)
Nigeria (NG)North Macedonia (MK)Norway (NO)Pakistan (PK)Palestine (PS)Panama (PA)Paraguay (PY)
Peru (PE)Philippines (PH)Poland (PL)Portugal (PT)
Romania RO)
Russia (RU)
Saudi Arabia (SA)Serbia (SRB)
Singapore (SG)Slovak Republic (SK)Slovenia (SI)South Africa (ZA)
Spain (ES)Sri Lanka (LK)
Sudan (SD)
Sweden (SW)Switzerland (CH)
Syrian Arab Republic (SY)
Thailand (TH)Tunisia (TN)Türkiye (TR)Ukraine (UA)United Arab Emirates (UAE)
United Kingdom (UK)
United States (US)Uruguay (UY)
Vietnam (VN)
Zambia (ZM)
Zimbabwe (ZW)

Regional Federations

Arab Federation of Clinical Biology (AFCB)
African Federation of Clinical Chemistry (AFCC)
Asia-Pacific Federation for Clinical Biochemistry
and Laboratory Medicine (APFCB)
European Federation of Clinical Chemistry
and Laboratory Medicine (EFLM)
Latin America Confederationof Clinical Biochemistry (COLABIOCLI)North American Federation of Clinical Chemistry
and Laboratory Medicine (NAFCC)

Abbott Laboratories
Agappe Diagnostics Ltd
Arkray Inc.
Asahi Kasei Pharma Corp.
Asesores de Calidad para
Laboratorios
Autobio Diagnostics Co. Ltd.
Beckman Coulter, Inc.
Becton Dickinson
Beijing Wantai BiologicalPharmacy Enterprise Co. Ltd
Bio Rad Laboratories
Biomasterclin Laboratorios
Venezuela
Brooks Automation Italy Srl
Controllab
C.P.M. Compagnia Per La
Medicina® Srl
Diagnostica Stago
Diasorin Spa
DiaSys Diagnostic Systems
DIRUI
Gmbh
Guangzhou Wondfo Biotech
Co., LtdET Healthcare Inc.
Fujifilm Wako Pure Chemical
Corporation
Fujirebio-Europe
Gentian As
Greiner Bio-One
Helena Biosciencies Europe
Hemas Hospital Pvt
Hytest Ltd.
I-Sens, Inc.
Immunodiagnostic Systems IDS Instand e.V.
Instrumentation Laboratory
Jiangsu Bioperfectus

Technologies Co. Ltd.
Labor Team W Ag
Labor Dr. Wisplinghoff
Lifotronic Technology Co. Ltd
Lumiradx Uk Ltd.
Maccura Biotechnology Co.,Ltd.
Medicalsystem Biotechnology
Co., Ltd.
Medix Biochemica
Menarini Diagnostics
Mindray
Nittobo Medical Co. Ltd.
Oneworld Accuracy
PerkinElmer
Phc Europe B.V.
Quality Academics, S.C.
Quidelortho
Radiometer Medical Aps
Randox Laboratories Ltd.
Roche Diagnostics Gmbh
Sansure Biotech Inc
Sebia S.A.
Sentinel Ch Spa
Shanghai KehuaBioengineering Co., Ltd.
Shenzhen Yhlo Biotech
Siemens Healthcare
Diagnostics
Snibe Co., Ltd
Synlab International Gmbh
Sysmex Europe Gmbh
Technogenetics
The Binding Site Group Ltd.
Thermo Fisher ScientificTosoh Corporation
United Robotics Group Gmbh
Zybio

Affiliate Members

Botswana: Institute of Clinical Laboratory Professionals
Brazil: Sociedade Brasileira de Patologia Clínica / Medicina
Laboratorial (SBPC/ML)
China: Lab Medicine Committee, China Association of Medical
Equipment (LMC)
Egypt: Egyptian Association of Healthcare Quality and Patient
SafetyFrance: French National Network of Accredited Laboratories ofMedical Biology (LABAC)
India: Association of Medical Biochemists of India (AMBI)
Iran: Iranian Association of Clinical Laboratory Doctors (IACLD)
Jordan: Society for Medical Technology & Laboratories (SMTL)
Kazakhstan: Public Association - Federation of Laboratory
Medicine (FLM)
Mexico: Federación Nacional de Químicos Clínicos (CONAQUIC
A.C.)
Mexico: Colegio Nacional de Químicos Clínicos en Medicina deLaboratorio (CONQUILAB)
Mexico: Federación Nacional de Colegios Profesionales de laQuímica Clínica, A.C. (FENACQC)
Nepal: Nepalese Association for Clinical Chemistry (NACC)
Philippines: Philippine Council for Quality Assurance in ClinicalLaboratories (PCQACL)
Romania: Order of the Biochemists, Biologists, Chemists in
Romanian Health System (OBBCSSR) Serbia: Serbian Society for
Clinical Laboratory Medicine and Science (SCLM)
Spain: Andalusian Society for Clinical Analysis and Laboratory
Medicine (SANAC)
Spain: Asociación Española de Biopatología Médica - Medicinade Laboratorio (AEBM-ML)
Spain: Asociación Española de Farmacéuticos Analistas (AEFA)
Sri Lanka: College of Chemical Pathologists of Sri Lanka (CCPSL)
Türkiye: Society of Clinical Biochemistry Specialists (KBUD)
Ukraine: Association for Quality Assurance of Laboratory
Medicine (AQALM)
United Arab Emirates: Genetic Diseases Association (UAEGDA)

43

enewsPublisher
Communications and Publications Division(CPD) of the IFCCThe Communications and Publications
Division publishes ten editions of the e-Newsper year, including two double issues.
EditorKatherina Psarra, MSc, PhD
Department of Immunology Histocompatibility Evangelismos Hospital,
Athens, Greece
E-mail: enews@ifcc.org
The eNews is distributed to all IFCC
members registered on-line to receive it andto all IFCC sponsors.
Deadlines for submissions to the eNews
N° 1/2 – January/February: by mid January
N° 3 – March: by mid February
N° 4 – April: by mid March
N° 5 – May: by mid April
N° 6 – June: by mid May
N° 7/8 – July/August: by mid June
N° 9 – September: by mid August
N° 10 – October: by mid September
N° 11 – November: by mid October
N° 12 – December: by mid November
If you want to submit an article oradvertisement to be published in the eNews,
send it to: Katherina Psarra, Editor, IFCC
eNews
E-mail: enews@ifcc.org

Copyright © 2024 IFCC. All rights reserved.
Contents may not be reproduced without
the prior permission of the Communications
and Publications Division (CPD) of the IFCC.

44